top of page

By:

Subhash Kaushik and Kishore Paknikar

21 August 2024 at 11:16:39 am

Homoeopathy, As We Know It

When NASA searches for life beyond Earth, it speaks of searching for “life, as we know it.” Those five words capture one of the most important principles of science. If life exists elsewhere in the universe, it may not resemble the life we know on Earth. Scientists therefore do not search for the unknown using yesterday’s assumptions. They search with better instruments, better questions, and an open mind. The same principle has guided every major scientific breakthrough. Every generation...

Homoeopathy, As We Know It

When NASA searches for life beyond Earth, it speaks of searching for “life, as we know it.” Those five words capture one of the most important principles of science. If life exists elsewhere in the universe, it may not resemble the life we know on Earth. Scientists therefore do not search for the unknown using yesterday’s assumptions. They search with better instruments, better questions, and an open mind. The same principle has guided every major scientific breakthrough. Every generation mistakes the limits of its instruments for the limits of nature. Microorganisms influenced human life long before the microscope revealed them. Most stomach ulcers were blamed on stress until the discovery of Helicobacter pylori changed medicine forever. Casting Aspersions The same lesson applies to homoeopathy. For more than two centuries, homoeopathy has occupied a unique place in medicine. It has been practised across the world, integrated into healthcare systems in many countries and trusted by millions of patients. At the same time, it has remained one of the most debated systems of medicine. Critics have questioned not merely whether it works, but whether it could work at all. Most medical debates begin after a treatment has shown some benefit. Homoeopathy has often been judged before the scientific discussion could move beyond its proposed mechanism. Homoeopathic medicines are diluted to such an extent that little or none of the original substance is expected to remain. If almost nothing remains, how can anything produce a biological effect? Judged by the chemistry and analytical methods available during the nineteenth and much of the twentieth century, that conclusion appeared entirely reasonable. Science, however, does not stand still. Its greatest strength is not certainty but self-correction. New instruments often compel scientists to revisit old conclusions. Advances in nanoscience, materials science and analytical chemistry now allow researchers to examine highly diluted preparations in ways that earlier generations simply could not. Research from India and other countries has reported observations, including measurable physicochemical features in some highly diluted preparations, that have reopened scientific discussion. Not every finding has been independently reproduced, and many questions remain unanswered. Yet one conclusion is becoming increasingly difficult to dismiss. The scientific basis for rejecting homoeopathy without further investigation is no longer as strong as it once appeared. Changing Perceptions Yesterday’s science asked whether homoeopathy was possible. Today’s science is increasingly asking how highly diluted preparations should be investigated using the best tools available. The placebo argument deserves similar attention. Critics frequently argue that any benefit observed with homoeopathy is simply the placebo effect. There is no doubt that placebo is real. Confidence in a physician, expectation of recovery, and the body’s own healing mechanisms influence outcomes in every branch of medicine. More than two centuries ago, physicians recognized that nature itself plays a powerful role in healing. That observation applies not only to homoeopathy but to every therapeutic system, including modern medicine. Homoeopathy has been reported to produce responses not only in adults but also in infants, animals and even plants, where expectation and belief cannot readily account for the observations. These reports do not, by themselves, prove the effectiveness of homoeopathy. Scientific conclusions require rigorous, reproducible and independently verified evidence. They do, however, raise a legitimate scientific question. If placebo cannot adequately explain every reported observation, what does? The answer cannot come from opinion. It can come only from careful scientific investigation. This is precisely how science has always progressed. It does not reject difficult questions because they challenge accepted thinking. Nor does it accept extraordinary claims without evidence. It designs better experiments. India is uniquely positioned to lead this next phase of inquiry. It possesses one of the world’s largest networks of qualified homoeopathic physicians, teaching institutions, hospitals and patients. Equally important, it has created a dedicated research ecosystem through the Central Council for Research in Homoeopathy (CCRH), the apex research organisation under the Ministry of Ayush, Government of India. Its mandate is neither to defend tradition nor to promote belief. Its responsibility is to generate credible evidence through laboratory research, well-designed clinical studies, public health investigations and collaborations with leading scientific institutions. The history of science repeatedly reminds us that ideas are not accepted because they are popular, nor rejected because they are unconventional. They are judged by evidence. Homoeopathy should be no exception. It should neither receive special privilege nor face special prejudice. It should be subjected to exactly the same standards expected of every other branch of medicine. That is the spirit in which this article has been written. One of us comes from a lifetime devoted to homoeopathic research, education and patient care. The other has spent decades in mainstream scientific research, institution building and promoting scientific temper. We share neither blind faith nor blind scepticism but a commitment to the scientific method. The larger lesson extends far beyond homoeopathy. Scientific progress depends on a willingness to revisit yesterday’s conclusions when today’s evidence demands it. Every generation mistakes the limits of its instruments for the limits of nature. The history of discovery is, in many ways, the history of overcoming those limits. Homoeopathy may ultimately confirm some long-held beliefs. It may equally challenge others. Science must remain prepared for either possibility. What it cannot afford is to stop asking questions simply because the answers appear inconvenient. Research does not exist to protect ideas. It exists to test them. Homoeopathy has earned that test. It deserves to be judged by the best evidence that twenty-first century science can generate, not by the limitations of nineteenth-century knowledge. (Dr. Kaushik is the Director General, Central Council for Research in Homoeopathy (CCRH), Ministry of Ayush, New Delhi; Dr. Paknikar is the Member, Scientific Advisory Board, CCRH, N. Delhi and ANRF Prime Minister Professor, COEP Technological University, Pune. Views personal.)

Lateral upgrade to ailing annihilation

Updated: Oct 21, 2024

Lateral upgrade to ailing annihilation

Being the first person from the private sector to be appointed as chairperson of Securities and Exchange Board of India (SEBI) as part of the government’s lateral initiative, Madhabi Puri Buch also holds the honour of being the first woman to hold the top post as capital market regulator.

But the laurels that the former private sector banker enjoyed in her earlier stint with ICICI Bank, was marred with allegations that she and her husband were having a stake in offshore entities, which were used to artificially inflate shares of Adani group companies.

Terming the allegation as `character assassination, Buch clarified that all disclosures have already been furnished and the fund in question did not invest in any securities involving the Adani group.

When it rains, it pours. This allegation was subsequently followed by Congress Party allegation that Buch had received salary and post-retirement benefits from ICICI Bank after she quit the private sector bank.

In its clarification to the stock exchanges, ICICI Bank asserted that the payments made to Buch were purely retirement benefits after her exit from the bank and they were neither salary nor employee stock options.

Prior to these allegations, Buch tenure at SEBI was all about bringing in quick reforms on operational issues by changing the format of consultation paper to bring in larger responses digitally. Being data savvy, the rationale of her decisions were democratic based on big data analysis derived from the responses received to the consultation papers.

Further she bifurcated the duties of the SEBI staff between operations and enforcement, which were done by the same persons earlier. Having worked for the private sector in the capital market domain space, Buch had a better understanding of the subject compared to officers from the administrative service in the past that reflected even in her orders as a whole-time director at SEBI before becoming the chairperson. As a whole time director at SEBI, her orders on adjudication issues were more directional to the capital market space, according to experts in the compliance space. She was also quick to revamp the old provisions of the 90s at SEBI.

Being tech and data savvy, Buch enhanced regulatory surveillance and detection of market manipulation, insider trading and fraud while also emphasizing on strengthening corporate governance by introducing stricter rules for independent directors and enhancing disclosures for related-party transactions.

To put in perspective, the annual report of the capital market regulator in the just concluded financial year revealed that the number of investigations related to insider trading jumped to 175 in 2023-24 from 85 in the preceding year while probes related to front running jumped over three times to 83 from 24 in the preceding year.

Transparency in mutual funds by implementing measures to protect retail investors along with tightening norms for initial public offers, particularly in the SME platforms were some of her other positive initiatives including confirmation of denial of any market rumours within 24 hours for the top 100 listed companies which will be extended to top 250 companies from December 1. However increased transparency and compliance with tightening regulations led to increased operational costs for the market participants and hence faced resistance from certain quarters. Born in 1966, Buch completed her primary education in Mumbai and graduated with specialization in Mathematics from Delhi and later obtained a management degree from Indian Institute of Management, Ahmedabad. In between, she got engaged to Dhawal Buch, a director at a consumer goods multinational at the age of eighteen and got married at the age of 21.

Besides ICICI Bank, Buch also worked as a lecturer at a college in England, worked at Greater Pacific Capital in Singapore and ICICI Securities as its CEO. She also worked as executive director on several private sector companies and as a consultant for New Development Bank (Brics Bank).

What now remains to be seen, is whether Buch, who survived the 26/11 terror attack when she along with her husband, was attending a meeting at Taj, be able to overcome the current ordeal. Keeping fingers crossed for the times to come.

Comments

bottom of page